

IBM Micromedex NeoFax and Pediatric Drug

IBM Micromedex
Data Sheet

Comprehensive, evidence-based resource for neonatal and pediatric patients to help

Highlights

Decrease the risk for dosing errors in the most vulnerable patients



Population-specific drug dosing information

Enhance clinician knowledge of neonatal and pediatric drug information



Patient-specific drug dosing calculators

Save clinicians time in calculating drug dosages



Neonatal and pediatric drug monographs



Enteral nutrition comparison tables

Infants and children are an especially vulnerable patient population, particularly with regard to medication safety.^{1,2} In fact, it's estimated that neonatal and pediatric patients are at least three times more prone to harm from adverse drug events and medication errors than the adult population.^{2,3,4,5}

IBM® Micromedex® NeoFax® and Pediatric Drug is an internet-based solution that addresses the unique needs of these patients to enable clinicians to make safer, more informed decisions about their medications.

Population-specific drug information

Micromedex NeoFax and Pediatric monographs are focused specifically on neonatal or pediatric drug therapy. The content is evidence-based, fully referenced, off-label focused and designed to allow clinicians quick and reliable access to only the most population-specific information.

With Micromedex NeoFax and Pediatric Drug, the patient populations of both IBM® Micromedex® NeoFax® and IBM® Micromedex® Pediatric Drug are available within the same interface, providing one source of relevant drug knowledge—from the most premature neonate, up to age 18. End-to-end AI Drive productivity with a unified, fully governed platform.

Patient-specific dosing calculators

The Micromedex NeoFax and Pediatric Drug solution includes dosing calculators for every drug in the individual solutions. These age- and indication-specific calculators are prepopulated with evidence-based recommendations that address dose, concentration and administration.

This powerful clinical decision support functionality provides clinicians with the dosage options for each patient quickly. It also provides warning messages for out-of-range values, working to significantly decrease the risk for dosing errors.

Enteral nutrition support

The enteral formula database within Micromedex NeoFax and Pediatric Drug is an additional resource to support the nutritional health and well-being of neonatal and pediatric patients.

With important information about infant formula and human milk fortifiers, this feature allows for comparison of multiple products to facilitate selection of the most appropriate nutritional support product.

Amphotericin B Liposome

Drug
Find a Pediatric drug

Neonatal Pediatric

Dosing/ Administration
Dose
Uses
Administration
View Full Document
Print

Medication Safety
Adverse Effects
Solution Compatibility
Solution Incompatibility
Monitoring

Mechanism Of Action/
Pharmacokinetics
Pharmacology

About
Special Considerations/
Preparation
References

NON-HIV Infected

Blastomycosis, Severe Disease: 3 to 5 mg/kg IV once daily for 1 to 2 weeks, followed by stepdown therapy with oral itraconazole 10 mg/kg/day orally (maximum 400 mg/day) in 2 divided doses for total of 12 months [1].

Cryptococcosis Meningitis and Disseminated Disease: 5 mg/kg IV once daily, in combination with flucytosine 25 mg/kg orally 4 times daily. Followed by fluconazole 10 to 12 mg/kg orally daily for 5 weeks as consolidation therapy [2].

Febrile Neutropenia, Empiric Treatment: 3 mg/kg IV once daily [3][4][5].

Histoplasmosis, Progressive Disseminated Histoplasmosis (intolerant to conventional amphotericin B): 3 to 5 mg/kg IV once daily for 4 to 6 weeks [6].

Infective endocarditis Older than infants: 3 to 5 mg/kg/day IV in a single dose with or without fucytosine 150 mg/kg/day orally divided every 6 hours. Duration is generally 4 to 6 weeks [7].

Ask Watson

Peace of mind when it matters most

Micromedex NeoFax and Pediatric Drug builds on the 25-plus-year reputation of Micromedex NeoFax as one of the leading neonatal drug information resources. The neonatal and pediatric content is backed by the comprehensive editorial processes and clinical rigor of IBM® Micromedex®, using evidence-based data developed after careful review of the population-specific research literature.

Get connected

email: watsonh@us.ibm.com

About IBM Watson Health

Each day, professionals throughout the health ecosystem make powerful progress toward a healthier future. At IBM Watson Health, we help them remove obstacles, optimize efforts and reveal new insights to support the people they serve. Working across the landscape, from payers and providers to governments and life sciences, we bring together deep health expertise; proven innovation; and the power of artificial intelligence to enable our customers to uncover, connect and act – as they work to solve health challenges for people everywhere.

For more information on IBM Watson Health, visit:
ibm.com/watsonhealth

© Copyright IBM Corporation 2018

IBM Corporation
Route 100
Somers, NY 10589

Produced in the United States of America
May 2018

IBM, the IBM logo and ibm.com and IBM Watson Health are trademarks of IBM Corporation in the United States, other countries or both. Truven Health Analytics and its respective logo are trademarks of Truven Health Analytics in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies. A current list of IBM trademarks is available on the Web at "Copyright and trademark information" at www.ibm.com/legal/copytrade.shtml.

This document is current as of the initial date of publication and may be changed by IBM at any time. Not all offerings are available in every country in which IBM operates.

The information in this document is provided "as is" without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. IBM products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it.

IBM does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation.

The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user's responsibility to evaluate and verify the operation of any other products or programs with IBM product and programs.

Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. IBM systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. IBM does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.

Footnotes

1 American Academy of Pediatrics Steering Committee on Quality Improvement and Management and Committee on Hospital Care: Policy Statement – Principles of pediatric patient safety: Reducing harm due to medical care. Pediatrics 2011;127:1199-1210, <http://pediatrics.aappublications.org/content/pediatrics/127/6/1199.full.pdf>

2 Kaushal R, Bates DW, Landrigan C, et al: Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-2120, <https://psnet.ahrq.gov/resources/resource/2146>

3 Stavroudis TA, Shore AD, Morlock L, et al: NICU medication errors: Identifying a risk profile for medication errors in the neonatal intensive care unit. J Perinatol 2010;30:459-468, <https://psnet.ahrq.gov/resources/resource/17387>

4 The Joint Commission: Sentinel event alert: Preventing pediatric medication errors. Issue 39, April 11, 2008. Available at: http://www.jointcommission.org/assets/1/18/SEA_39.PDF
Last accessed 7/21/2011

5 Suresh G, Horbar JD, Plsek P, et al: Voluntary anonymous reporting of medical errors for neonatal intensive care. Pediatrics 2004;113:1609-1618, <http://www.medscape.com/medline/abstract/15173481>

